- Research article
- Open Access
Effects of urodilatin on natriuresis in cirrhosis patients with sodium retention
BMC Gastroenterology volume 7, Article number: 1 (2007)
Sodium retention and ascites are serious clinical problems in cirrhosis. Urodilatin (URO) is a peptide with paracrine effects in decreasing sodium reabsorption in the distal nephron. Our aim was to investigate the renal potency of synthetic URO on urine sodium excretion in cirrhosis patients with sodium retention and ascites.
Seven cirrhosis patients with diuretics-resistant sodium retention received a short-term (90 min) infusion of URO in a single-blind, placebo-controlled cross-over study. In the basal state after rehydration the patients had urine sodium excretion < 50 mmol/24 h.
URO transiently increased urine sodium excretion from 22 ± 16 μmol/min (mean ± SD) to 78 ± 41 μmol/min (P < 0.05) and there was no effect of placebo (29 ± 14 to 44 ± 32). The increase of URO's second messenger after the receptor, cGMP, was normal. URO had no effect on urine flow or on blood pressure. Most of the patients had highly elevated plasma levels of renin, angiotensin II and aldosterone and URO did not change these.
The short-term low-dose URO infusion increased the sodium excretion of the patients. The increase was small but systematic and potentially clinically important for such patients. The small response contrasts the preserved responsiveness of the URO receptors. The markedly activated systemic pressor hormones in cirrhosis evidently antagonized the local tubular effects of URO.
Sodium and water retention occurring in decompensated cirrhosis and leading to ascites is a clinical challenge and may be difficult to treat [1–3]. Therapeutic possibilities include sodium restriction, diuretics and aldosterone antagonists, and in refractory cases repeated paracentesis, transjugular intrahepatic porto-systemic shunt (TIPS), or liver transplantation. Further pathophysiological insight and new treatment modalities are desirable. Any new drug with the potential of increasing sodium and water excretion in cirrhosis patients with refractory ascites and severe sodium retention will be a significant clinical improvement for this group of patients.
The atrial natriuretic peptide (ANP) has been investigated as such an alternative agent, but the benefits were quite modest [4–7]. Our group in previous works focused on the renal effects of synthetic urodilatin (URO), another member of the natriuretic peptide family, with dose-dependent renal effects in normal man [8, 9]. Endogenous URO is the product of a different posttranslational processing of pro-ANP that takes place in the distal tubule cells. URO released into the tubular lumen stimulates natriuretic peptide receptors on the luminal surface of tubular cells and thereby inhibits distal tubular sodium reabsorption . Specific guanylate cyclase-coupled receptors in the inner medullary collecting ducts are the physiological target sites for URO and cGMP is the second messenger for URO's biological actions. [11, 12]. Thus, URO is an intrarenal paracrine regulator of sodium and water homeostasis. Urine urodilatin excretion is normal in patients with cirrhosis even in the presence of marked sodium retention. The coexistence of increased ANP levels and normal urodilatin excretion suggests that in cirrhosis the two natriuretic peptides are regulated independently .
In patients with cirrhosis and light to moderate sodium retention we earlier showed that administration of synthetic URO more than doubled natriuresis and increased diuresis due to enhanced fluid delivery from the proximal tubules, and in addition, inhibited fractional sodium reabsorption in the distal nephron, as demonstrated by lithium clearance .
The aim of this study was to investigate the natriuretic and diuretic effects of synthetic URO in cirrhosis patients with severe sodium retention and ascites refractory to conventional diuretic therapy.
The inclusion criteria were: (1) presence of cirrhosis in a liver biopsy; (2) or anamnestic, clinical and laboratory evidence of cirrhosis including ascites (verified by ultrasound), oesophagogastric varices (verified by gastroscopy), hypoalbuminemia and reduced prothrombin index; (3) a 24-h urine sodium excretion <60 mmol; and (4) written informed consent. The exclusion criteria were: (1) primary kidney disease (s-creatinine > 200 μmol/L); (2) congestive heart failure; (3) diabetes; (4) haemoglobin < 6.0 mmol/L; and (5) a history of bladder dysfunction. The withdrawal criteria during or after the study were: (1) severe adverse events during or after URO, and (2) lack of urination at the appointed time points.
Seven cirrhosis patients with ascites refractory to pharmacotherapy were consecutively recruited in our department. Their mean age was 54 ± 7 years (mean ± SD), mean body weight 69 ± 13 kg; five men and two women. Three patients had cirrhosis verified by a liver biopsy. Four patients had oesophagogastric varices. All the patients had alcoholic liver disease. The basal characteristics of the patients including their MELD score are summarized in Table 1. All patients received diuretics as a combination therapy of spironolactone and furosemide. The patients had their diuretic treatment and hydration status adjusted in the time period between enrolment and the first study infusion day. The patients had normal ECG. Plasma-creatinine was 67 ± 19 μmol/L.
Informed written consent was obtained from all patients, and the study was approved by the local Ethics Commitee of Aarhus and the Danish National Board of Health; and it was performed in accordance with the Declaration of Helsinki.
It was a randomised, single-blind, placebo-controlled study with synthetic urodilatin (Boehringer Mannheim GmbH, Mannheim, Germany). Each patient participated on two study days. Each patient received, in a randomised order, a 90-min infusion of URO (20 ng kg body weight-1 min-1) and a 90-min infusion of placebo (PL). It thus was a cross-over design with a wash-out period of 2–3 days.
The lyophilised URO was dissolved in isotonic saline solution. Placebo was isotonic saline. Infusions were given by pump at a rate of 0.2 ml kg-1 h-1. In a patient of eg 70 kg bodyweight, the total infusion volume was 21 mL. The URO dose was chosen from previous observations with a threshold dose of 20 ng kg body weight-1 min-1 and risk of side effects with higher doses .
All patients were hospitalised during the study. A 24-h urine sample was collected before enrolment. There was a run-time of four to 14 days during which diuretic treatment was adjusted and stabilized, and it was discontinued the day before infusion of both URO and placebo, but continued in between the two study days. The patients fasted from midnight and took notes of the time points of last urination before sleep and morning urination, and the urine volume including nightly urine was measured (clearance period 1). On the study day, 200 mL of water was given orally every 30 min from 7:30 am till noon. The study comprised a pre-infusion phase of 90 min (7:30 am to 9 am; clearance period 2), the infusion phase of 90 min (9 am to 10:30 am; clearance periods 3 and 4) and a post-infusion phase of 90 min (10:30 am to noon; clearance periods 5 and 6). Urine was collected in consecutive 45-min clearance periods from 9 am. The morning urine and urine collected at 9 am were used as baseline (clearance periods 1 and 2). At 9 am, infusion was initiated. The patient was in supine position, except during urination, which took place in upright position.
Urine samples from the 24-h urine and clearance periods were analysed for sodium and potassium contents. At the beginning and end of each clearance period, venous blood samples were drawn for concentrations of sodium, renin, angiotensin II (AngII), aldosterone (Aldo), and cyclic guanosine monophosphate (cGMP). Blood was secured in the supine position and before urination and followed by administration of the same volume of isotonic saline i.v. Systemic blood pressure (BP) and heart rate (HR) were measured every 20 min from 8 am till noon.
Plasma sodium (PNa) and creatinine and urine sodium (UNa), potassium (UK) were determined by an autoanalyser (local Department of Clinical Biochemistry). Serum AngII, Aldo, renin and cGMP were determined by RIAs as described in detail earlier [8–10].
We investigated seven patients and one of these was excluded from data analysis due to incomplete urine collection during the study day. Data not showing normal distribution within the same group was analysed by non-parametric Friedmans ANOVA test followed by non-parametric Willcoxon paired samples test. For unpaired comparisons between the URO and the placebo group non-parametric Kruskall-Wallis ANOVA test was used followed by the ManWhitney test. The differences between groups were based on the relative changes (Δ) from pre-infusion levels. A P-value of 0.05 was the limit of significance. Mean values ± SD of the absolute and relative changes (Δ) from pre-infusion levels are presented. Pearson correlation coefficient was used to measure the relationship between two variables.
Urine sodium excretion rate (UNa)
The average 24-hour urine sodium excretion rate (UNa) was 35 ± 10 mmol/day (or 24 ± 9 umol/min) before study start. UNa baseline values are shown in Table 1. On average, URO increased UNa from 22 ± 16 μmol/min (mean ± SD) to 78 ± 41 μmol/min (P < 0.05) while there was no significant effect of placebo (29 ± 14 to 44 ± 32) (fig. 1). At the end of the study, there was no difference between URO and placebo (fig. 2). The relative changes, ΔUNa, from baseline following URO infusion, tripled in period 3 (P = 0.10) and rose 6-fold (P = 0.05) in period 4, with very large variation. Placebo had no appreciable effect (fig 2). Total sodium excretion during URO and placebo infusions is shown in Figure 3.
Urine flow rate (V)
V baseline values are shown in Table 1. On average, URO increased V from 0.81 ± 0.36 ml/min to 2.95 ± 2.54 ml/min, while placebo increased V from 1.29 ± 0.58 ml/min to 2.36 ± 2.45 ml/min. The relative change in urine flow after URO was marginally larger than after placebo in period 3 (URO, 240 ± 258 %; PL, 13 ± 60%; P = 0.07), but not in period 4 (URO, 337 ± 373%; PL, 52 ± 110%; P = 0.18), see Figure 4. Following infusion stop, V tended to decrease on the URO day compared to Placebo (P = 0.1).
Second messenger cGMP
URO infusion markedly increased serum cGMP (P < 0.01) (fig. 5).
The second messenger cGMP response was linked to the infusion of URO, but the serum level of cGMP achieved was independent of the level of urine sodium output, see Figure 6.
Serum renin, angiotensin II and aldosterone
Pre-infusion concentrations of renin, AngII and Aldo in serum are shown in Table 1. All except one patient had highly elevated hormone levels compared to values measured in normal man . Neither infusions changed any of these levels (data not shown). There was no significant inverse correlation between the baseline hormone levels and the natriuretic response to URO (fig. 7, 8, 9). However, the highest urine sodium output was measured in the only patient who had normal baseline concentration levels of all three hormones.
Systemic Blood Pressure (BP), Heart Rate (HR) and body weight
There was no significant difference in changes in these variables between URO and placebo infusions. There was a minor decrease of body weight both days.
One patient complained of dryness in the mouth, and another vomited once in the post-infusion phase of URO. One patient had a gradual drop in BP from 95/55 to 65/50 mmHg after 85 min of URO infusion. The infusion was completed, and the patient recovered in Trendelenburg.
The main finding of the present study was that short-term synthetic URO infusion induced increased natriuresis in cirrhosis patients with severe sodium retention. The effect was much smaller than in our previous studies in healthy subjects and patients with less advanced cirrhosis and minor sodium retention [8, 9, 14]. The cGMP response to URO was normal.
In the previous study we demonstrated increased delivery of isotonic fluid from the proximal tubule and decreased fractional distal tubular sodium reabsorption during a URO-infusion, using the lithium clearance technique . URO probably inhibited isotonic fluid reabsorption in the proximal tubule. Still, the mechanism of action of URO in the proximal nephron is unclear since proxinal tubule cells do not exhibit a cGMP response. The present investigation, in being a bed-side study, did not adopt radioactive tracers or the lithium clearance technique to delineate the tubular site of action of URO; we assume that the increased natriuresis was a result of both proximal and distal tubular action, as in our previous study.
The reason why the natriuretic response was weaker in the patients with refractory ascites is not clarified. Obvious differences between the patients with refractory ascites and less advanced cirrhosis are the high plasma levels of the anti-natriuretic hormones like renin, angiotensin II and aldosterone. The proximal tubular action of these anti-natriuretic hormones probably diminished distal tubular sodium delivery to the specific guanylate cyclase-coupled receptors in the inner medullary collecting ducts, the main target sites of URO. This is supported by the normal cGMP response. Likewise, the same hormones probably also antagonized the inhibitory effect of URO on isotonic fluid reabsorption in the proximal tubules. Both mechanisms would restrict normal tubular effects of URO.
The natriuretic effect of URO is mediated by cGMP, released from the URO receptor. The response of this second messenger was similar to the level measured after administration of synthetic URO in healthy subjects and in patients with less advanced cirrhosis [8, 14]. This indicates intact biological responsiveness of the URO receptors in severe sodium retainers, including peptide receptor coupling and intracellular URO signalling. The normal cGMP responses both in patients with normal and decreased sodium excretion point to dissociation between the biochemical (cGMP) and the physiologic (natriuresis) response to URO. This is in line with the prevention by the pressor hormones of urine sodium reaching the URO site of action. Still, we found no relation between the level of these hormones and the natriuretic effect of URO in our patients, but this was probably due mostly to the small number of patients.
In the present study the effects of URO on urine flow were highly variable but the overall impression was that URO tended to increase diuresis (fig. 3). This is in accordance with the mode of action of the peptide where water and sodium handling are coupled. In the same way as regarding natriuresis, the aquaretic effect of URO was much larger and more consistent in cirrhosis patients with less sodium retention .
The demonstrated renal pharmacodynamic effects of URO were short-lived (fig. 2) because of the short half-life (about 5 min) of URO. Therefore, there is also no reason to suspect a carry-over effect between study days.
We used a dose of 20 ng URO kg-1 min-1 since higher doses may lower systemic blood pressure [8, 9]. Accordingly, there was no appreciable effect on blood pressure. Adverse effects were minor except in one patient with a moderate fall of systolic blood pressure at the end of the URO infusion. A similar low frequency of adverse effects was observed in our previous study .
The patients continued on their adjusted medication and their usual fluid and food intake until the day before study start in order to study them in a clinically and physiologically stable phase, and also to minimize the discomforts of taking part in a study. The patients were not placed on a sodium controlling diet, but the identical baseline (pre-infusion) levels of urine sodium excretion on both study days suggest that the patients were in adequately stable sodium equilibrium. We stopped their diuretics first on the day before the infusion of either URO or placebo so that spironolactone and its metabolites may still have antagonized the tubular action of aldosterone and increased the delivery of sodium to the distal nephron and the site of action of URO and contributed to the increase in natriuresis. The cross-over design with an interval of two-three days between infusions likely, however, ensured identical conditions on both study days.
The mild increase of sodium excretion rate in the placebo group is well-known in clearance studies with water-loaded subjects. It is of no importance in healthy subjects responding vividly to URO, but it calls for special care in the interpretation of the natriuretic effect of URO in the presented sodium retainers.
The clinical implications of URO are not clarified. Stimulation of the sympathetic nervous system and activation of the renin-angiotensin-aldosterone system play a pivotal role in the resistance to conventional diuretics in advanced cirrhosis. As mentioned above, similar forces are most likely the cause of the relative resistance to URO. Maneuvres that increase distal tubular sodium delivery may restore the renal responsiveness to URO in advanced cirrhosis. If so, URO is not potent alone, but may be so in combination with loop of Henle diuretics and distal tubular diuretics.
We are aware of the limitations of the study as a result of the small number of patients. Larger trials are needed to confirm the results before it is possible to discuss the clinical use of URO in cirrhosis patients. The clinical value of URO has been investigated in other diseases and mostly with disappointing outcomes. URO was found to have no beneficial effect in acute renal failure or in prevention of renal impairment following liver transplantation [15, 16]. In a recent study on decompensated chronic heart failure a 24-hour infusion of URO substantially decreased cardiac filling pressure because of the vasodilatory effects, but no improved renal function was reported .
The URO infusion transiently shifted our patients from a stage with threatening hepatorenal syndrome to a stage with controllable salt balance. Although the demonstrated natriuretic effect was physiologically small, it may nonetheless be clinically important by lifting the patients over the threshold of irreversible decompensation. Alternatively, the results can be taken to show that the mechanisms that favour sodium excretion seem to be operative if the sodium retaining systems can be de-activated.
These patients with decompensated cirrhosis and severe sodium retention responded systematically but modestly to a short-term low-dose URO infusion compared to the large natriuretic response observed in previous studies with healthy subjects and patients with less advanced cirrhosis. The only small natriuretic and diuretic response contrasted the preserved biologic responsiveness of the URO receptors in the inner medullary collecting ducts. This was probably due to the activation of the systemic mechanisms behind sodium and water retention in cirrhosis, evidently antagonizing the tubular effects of URO.
Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J: Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988, 5: 1151-1157.
Epstein M: Hepatorenal syndrome: Emerging perspectives of pathophysiology and therapy. J Am Soc Nephrol. 1994, 4: 1735-1753.
Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, Ring-Larsen H, Scholmerich J: Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology. 1996, 1: 164-176. 10.1002/hep.510230122.
Brenner BM, Ballermann BJ, Gunning ME, Zeidel ML: Diverse biological actions of atrial natriuretic peptide. Physiol Rev. 1990, 3: 665-699.
Beutler JJ, Koomans HA, Rabelink TJ, Gaillard CA, Van Hattum J, Boer P, Dorhout Mees EJ: Blunted natriuretic response and low blood pressure after atrial natriuretic factor in early cirrhosis. Hepatology. 1989, 2: 148-153.
Petrillo A, Scherrer U, Gonvers JJ, Nussberger J, Marder H, de Vane P, Waeber B, Hofstetter JR, Brunner HR: Atrial natriuretic peptide administration as intravenous infusion or bolus injection to patients with liver cirrhosis and ascites. J Cardiovasc Pharmacol. 1988, 3: 279-285.
Brenard R, Moreau R, Pussard E, Champigneulle B, Gaudin C, Hadengue A, Braillon A, Lebrec D: Hemodynamic and sympathetic responses to human atrial natriuretic peptide infusion in patients with cirrhosis. J Hepatol. 1992, 14: 347-356. 10.1016/0168-8278(92)90182-O.
Carstens J, Jensen KT, Pedersen EB: Effect of urodilatin infusion on renal haemodynamics, tubular function and vasoactive hormones. Clin Sci. 1997, 92: 397-407.
Carstens J, Jensen KT, Pedersen EB: Metabolism and action of urodilatin infusion in healthy volunteers. Clin Pharmacol Ther. 1998, 64: 73-86. 10.1016/S0009-9236(98)90025-X.
Saxenhofer H, Fitzgibbon WR, Paul RV: Urodilatin: binding properties and stimulation of cGMP generation in rat kidney cells. Am J Physiol. 1993, 264: F267-273.
Schulz-Knappe P, Forssmann K, Herbst F, Hock D, Pipkorn R, Forssmann WG: Isolation and structural analysis of urodilatin, a new peptide of the cardiodilati-(ANP)-family, extracted from human urine. Klin Wochenschr. 1988, 66: 752-759. 10.1007/BF01726570.
Greenwald JE, Needlemann P, Wilkins MR, Schreiner GF: Renal synthesis of atriopeptin-like protein in physiology and pathophysiology. Am J Physiol. 1991, 260: F602-607.
Salo J, Jimenez W, Kuhn M, Gines A, Gines P, fernandez-Esparrach G, Angeli P, Claria J, Bataller R, Arroyo V, Forssmann WG, Rodes J: Urinary excretion of urodilatin in patients with cirrhosis. Hepatology. 1996, 24: 1428-1432. 10.1002/hep.510240621.
Carstens J, Greisen J, Jensen KT, Vilstrup H, Pedersen EB: Renal effects of a urodilatin infusion in patients with liver cirrhosis, with and without ascites. J Am Soc Nephrol. 1998, 9: 1489-1498.
Meyer M, Pfarr E, Schirmer G, Uberbacher HJ, Schope K, Bohm E, Fluge T, Mentz P, Scigalla P, Forssmann WG: Therapeutic use of the natriuretic peptide ularitide in acute renal failure. Ren Fail. 1999, 21: 85-100.
Langrehr JM, Kahl A, Meyer M, Neumann U, Knoop M, Jonas S, Steinmuller T, Bechstein WO, Frei U, Forsmann WG, Neuhaus P: Prophylactic use of low-dose urodilatin for prevention of renal impairment following liver transplantation: a randomized placebo-controlled study. Clin Transplant. 1997, 11: 593-598.
Mitrovic V, Lüss H, Nitsche K, Forssmann K, Maronde E, Fricke K, Forsmann WG, Meyer M: Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial. Am Heart J. 2005, 150: 1239e1-1239e8. 10.1016/j.ahj.2005.01.022.
The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1471-230X/7/1/prepub
We thank Rikke Andersen and Lisbeth Mikkelsen for their skillful technical assistance. Urodilatin was kindly donated by Boehringer Mannheim GmbH, Mannheim, Germany. There are no further sources of funding for the study, authors, or preparation of the manuscript.
The author(s) declare that they have no competing interests.
JC have contributed to acquisition of data, analysis and interpretation of data and have been involved in drafting the manuscript.
HG have contributed to acquisition of data, made substantial contributions to analysis and interpretation of data as well as being involved in drafting the manuscript.
HKL have made substantial contribution to acquisition of data.
EBP have made contribution to interpretation of data, critical revision of the manuscript and technical/material support.
HV conceived of the study, participated in its design and coordination, helped to critical revise manuscript and gave administrative and technical/material support.
All authors read and approved the final manuscript.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Carstens, J., Grønbæk, H., Larsen, H.K. et al. Effects of urodilatin on natriuresis in cirrhosis patients with sodium retention. BMC Gastroenterol 7, 1 (2007). https://0-doi-org.brum.beds.ac.uk/10.1186/1471-230X-7-1
- Atrial Natriuretic Peptide
- Sodium Retention
- Cirrhosis Patient
- Urine Sodium Excretion
- Refractory Ascites